Melanoma: Recognition, Risk Factors, and Next Steps

Melanoma is the most dangerous form of skin cancer, arising from the melanocytes — pigment-producing cells found primarily in the skin but also in the eyes and mucous membranes. Although melanoma accounts for only about 1% of all skin cancer cases in the United States, it is responsible for the large majority of skin cancer deaths (American Cancer Society, Cancer Facts & Figures 2023). This page covers the biological mechanics of melanoma development, the established risk factors, classification systems used by clinicians, and the structured framework for recognition and follow-up.

Definition and Scope

Melanoma originates in melanocytes, the cells responsible for producing melanin, the pigment that gives skin its color. When melanocytes undergo malignant transformation — typically driven by DNA damage — they can proliferate uncontrollably and, if not detected early, invade deeper skin layers and spread to lymph nodes and distant organs through a process called metastasis.

The National Cancer Institute (NCI) estimates that approximately 97,610 new cases of melanoma of the skin will be diagnosed in the United States in 2023, with roughly 7,990 deaths attributable to the disease that year. Five-year survival rates drop sharply with stage at diagnosis: localized melanoma carries a 5-year relative survival rate of approximately 99%, while distant metastatic melanoma falls to approximately 35% (NCI SEER Database).

The skin cancer types and warning signs resource on this network provides broader context across all skin cancer categories, including basal cell and squamous cell carcinoma, which differ substantially in metastatic potential from melanoma.

Core Mechanics or Structure

Melanoma development follows a multistep process rooted in genomic instability. Ultraviolet (UV) radiation — particularly UVB at wavelengths of 280–315 nanometers — causes cyclobutane pyrimidine dimers and 6-4 photoproducts to form in DNA. When cellular repair mechanisms fail to correct these lesions before cell division, mutations accumulate.

Two genes are implicated with particular frequency. The BRAF gene, specifically the V600E point mutation, is identified in approximately 50% of cutaneous melanomas (Cancer Genome Atlas Network, Nature, 2015). The NRAS gene is mutated in roughly 15–20% of cases. These driver mutations activate the MAPK/ERK signaling pathway, promoting unchecked cell proliferation.

Melanoma progresses through two recognized growth phases. The radial growth phase involves lateral spread within the epidermis and superficial dermis — a stage associated with lower metastatic risk. The vertical growth phase marks invasion into the deeper dermis and subcutaneous tissue, enabling access to lymphatic and vascular channels and substantially elevating the risk of systemic spread. Breslow thickness — measured in millimeters from the top of the granular layer to the deepest tumor cell — remains the primary pathological determinant of prognosis after skin biopsy.

Causal Relationships or Drivers

The established risk architecture for melanoma spans environmental exposures, genetic predisposition, and phenotypic characteristics.

UV Exposure constitutes the most modifiable environmental driver. Intermittent, intense UV exposure — characteristic of sunburn episodes — is more strongly associated with melanoma than cumulative chronic exposure, according to the World Health Organization's International Agency for Research on Cancer (IARC). Indoor tanning devices, classified by IARC as Group 1 carcinogens (definitively carcinogenic to humans), increase melanoma risk by approximately 75% when first use occurs before age 35 (IARC Monograph Vol. 100D).

Genetic and Familial Factors include germline mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A), which are found in approximately 40% of families with 3 or more affected first-degree relatives. The MC1R gene variant, associated with red hair and fair skin, also elevates risk independent of UV exposure patterns.

Phenotypic Risk Markers — light skin, blue or green eyes, red or blonde hair, and a tendency to freckle or burn — reflect reduced constitutive melanin production and heightened UV susceptibility. Individuals with more than 50 common nevi (moles) carry a measurably elevated lifetime risk compared to the general population (NCI Physician Data Query).

Personal or Family History of melanoma increases the probability of a second primary melanoma by a factor of approximately 9 compared to the general population (NCI SEER).

The regulatory context for dermatology page documents how federal and state frameworks — including FDA oversight of tanning devices and sunscreen formulations — intersect with melanoma prevention policy.

Classification Boundaries

The World Health Organization Classification of Skin Tumours (5th edition, 2018) and the American Joint Committee on Cancer (AJCC) 8th Edition Staging Manual define the primary classification systems for melanoma.

By Histological Subtype:

By AJCC Staging (Stage I–IV):

Dermoscopy and skin imaging tools assist in clinical subtype identification before biopsy confirmation.

Tradeoffs and Tensions

Several legitimate tensions exist within melanoma management that reflect ongoing clinical and scientific debate.

Excision margins remain contested at the border between Stage I and Stage II disease. A 1 cm margin is supported for tumors ≤1 mm Breslow thickness, while 2 cm margins are recommended for tumors >2 mm thick per National Comprehensive Cancer Network (NCCN) guidelines. Intermediate-thickness melanomas (1–2 mm) sit in a zone where multiple randomized trials have shown non-inferiority of 1 cm versus 2 cm margins, but the oncologic community has not reached full consensus.

Sentinel lymph node biopsy (SLNB) in intermediate-thickness melanomas (1–4 mm) provides staging information but has not consistently demonstrated an improvement in overall survival in randomized data, including the Multicenter Selective Lymphadenectomy Trial (MSLT-II). This creates a tension between prognostic value (where SLNB is informative) and therapeutic benefit (which remains debated).

Surveillance intensity after definitive treatment lacks a single universally adopted protocol. Imaging frequency, biomarker monitoring, and follow-up interval vary across institutions, reflecting genuine uncertainty about optimal post-treatment monitoring.

Common Misconceptions

Misconception: Melanoma only occurs in sun-exposed skin.
Acral lentiginous melanoma develops on the palms, soles, and nail beds — areas with minimal UV exposure. Ocular and mucosal melanomas arise in sites with no direct sun exposure at all.

Misconception: Dark-skinned individuals are not at risk.
While overall incidence rates are lower in populations with higher constitutive melanin, melanoma in Black patients is disproportionately diagnosed at later stages, correlating with higher mortality. The acral lentiginous subtype, which is stage-for-stage equally aggressive, predominates in this population (NCI SEER data).

Misconception: A changing mole is always melanoma.
Moles change for benign reasons, including hormonal fluctuation and minor trauma. The ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolution) were developed as clinical screening heuristics, not diagnostic criteria. Biopsy remains the definitive diagnostic step.

Misconception: Thick, dark sunscreen fully eliminates risk.
Sunscreen reduces UV-induced DNA damage but does not block all UVA radiation implicated in melanoma development. The FDA's sunscreen monograph, updated through the 2019 Proposed Rule on Sunscreen Drug Products, categorizes SPF 15+ as potentially contributing to skin cancer risk reduction when combined with other protective measures — but does not authorize a "complete protection" claim.

Checklist or Steps (Non-Advisory)

The following represents a structured recognition and documentation framework based on published clinical guidelines from the American Academy of Dermatology (AAD) and NCI:

  1. Identify the lesion category — distinguish between a new lesion, a changing existing nevus, and a stable background mole during a full-skin examination.
  2. Apply ABCDE assessment — document Asymmetry, Border irregularity, Color variation (multiple hues within one lesion), Diameter >6 mm, and Evolution (any change in size, shape, color, or symptom over time).
  3. Note the "ugly duckling" sign — flag any lesion that appears clinically distinct from the patient's overall nevus pattern, a criterion supported by the AAD's melanoma screening recommendations.
  4. Document site, size, and dermoscopic features — standardized dermoscopic patterns (atypical pigment networks, regression structures, blue-white veil) inform the differential before biopsy.
  5. Record personal and family risk history — prior melanoma, CDKN2A status if known, immunosuppression, and tanning device use.
  6. Biopsy classification — full-thickness excisional biopsy with 1–3 mm margins is the preferred technique per AAD guidelines; shave biopsies are generally avoided for suspected melanoma due to sampling depth limitations.
  7. Pathology reporting — confirm Breslow thickness, Clark level, ulceration, mitotic rate, and margin status as required elements under the College of American Pathologists (CAP) melanoma reporting protocol.
  8. Stage assignment — apply AJCC 8th Edition criteria to determine stage and guide workup decisions including imaging and lymph node evaluation.

Reference Table or Matrix

Melanoma Subtypes: Key Distinguishing Features

Subtype Approximate Frequency Typical Location Growth Pattern Common Demographics
Superficial spreading ~70% Back (men), legs (women) Radial then vertical All adults
Nodular ~15–20% Trunk, head, neck Vertical from onset Middle-aged to older adults
Lentigo maligna ~10–15% Face, neck Slow radial (years) Older adults, chronically sun-damaged skin
Acral lentiginous ~5% (overall) Palms, soles, nail beds Radial then vertical More prevalent in Black, Asian, Hispanic populations
Mucosal <1% (cutaneous) Oral, nasal, genital mucosa Variable All populations equally

AJCC 8th Edition Stage Summary

Stage Characteristics 5-Year Relative Survival (NCI SEER)
Stage I Thin, localized; no ulceration or ≤0.8 mm ulcerated ~98–99%
Stage II Thicker or ulcerated, no nodal involvement ~82–94%
Stage III Regional lymph node or in-transit metastasis ~63–77%
Stage IV Distant metastasis ~23–35%

Survival estimates drawn from NCI SEER Cancer Statistics. Stage-specific ranges reflect subcategory variation within each stage grouping.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)